HT-100

Rare skin disease biotech eyes $16 million IPO as trial results come in and cash runs out
Endpoints
Mon, 12/16/19 - 10:48 am
IPOs
Processa Pharmaceuticals
HT-100
Trial restart approval brings back DMD hope for Akashi
BioPharma Dive
Thu, 03/23/17 - 09:31 am
Akashi Therapeutics
Duchenne Muscular Dystrophy
clinical trials
HT-100
A patient in Akashi's suspended Duchenne MD trial dies
Fierce Biotech
Sat, 02/6/16 - 12:26 pm
Akashi Therapeutics
clinical trials
Duchenne Muscular Dystrophy
HT-100